R/R Colon Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

The most typical gastrointestinal cancer is colon cancer. Genetics, environmental exposure (including diet), and gastrointestinal inflammation are all part of the multifactorial pathological process that leads to its etiology. Third in line for fatal conditions is colorectal cancer. At the time of diagnosis, about 25% of patients have metastatic disease, and approx. When given a CRC diagnosis, 50-60% of patients develop metastatic disease. The third most common cancer in the country and the third leading cause of cancer-related death in both men and women in the country, colon cancer incidence and mortality have been steadily declining over the past few decades, with incidence falling by an average of 2.4% per year and mortality falling by an average of 2.2% per year from 2007 to 2016. Similar to the course of treatment for the initial colon cancer diagnosis, recurrent colon cancer may also be treated with a combination of surgery and systemic therapies, such as chemotherapy. Patients with metastatic colorectal cancer who have relapsed or are refractory to treatment typically receive multiple chemotherapy regimens.

Description

The most frequent cancer of the digestive system is colon cancer. Genetics, environmental exposure (including diet), and gastrointestinal inflammation are all part of the multifactorial pathological process that leads to its etiology. The third most common cause of death is colorectal cancer. At the time of diagnosis, about 25% of patients have metastatic disease, and. When given a CRC diagnosis, 50-60% of patients develop metastatic disease. It has been noted that men's CRC prognosis is negatively impacted by visceral obesity. About a quarter contributes to genetic susceptibility. The average time it takes for CRCs to develop is several years to several years, so it is critical to identify the condition as soon as it manifests. Predisposing factors for colorectal cancer (CRC) include a history of cholecystectomy, colon polyps, inflammatory bowel disease, diabetes, and colon polyps. Patients with localized, regional, and metastatic colon cancer had 5-year survival rates of 91%, 72%, and 13%, respectively. Due in large part to the discovery of molecular subtypes, the clinical outcome of MCRC has significantly improved. At the moment, the OS (median survival) is approximately. in the clinical trial group for 30 months and 2 years in the general population. Tumor molecular profiling is now frequently carried out to estimate the approx. Anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (mAB) therapy has a 40% response rate in wild-type (WT) RAS.

R/R Colon Cancer (Epidemiology)

The incidence and mortality of colon cancer in the United States have been steadily declining over the past few decades, with incidence falling by an average of 2.4% annually and mortality falling by an average of 2.2% annually from 2007 to 2016. Colon cancer is the third most common cancer in the country and the third leading cause of cancer-related death in both men and women. Young adults are also developing colon cancer at a higher rate. By 2022, 106,180 new cases of colon cancer will have been discovered in Americans, according to the American Cancer Society. Due to classification issues, the estimated death rate from colon cancer is 52,580 in 2022 (both are combined). Around 1,931,590 new cases of colon cancer will be diagnosed worldwide in 2020, making up 10% of all cancer cases. The incidence can vary by up to six times by location. South Asia has the lowest estimated rates (6.6 men and 4.4 women per 100,000) while southern Europe has the highest estimates (40.6 men and 24.5 women per 100,000). About 1.2 billion cases of colon cancer were reported globally. 2020 will see 935,173 deaths, or 9.4% of all cancer-related deaths.

R/R Colon Cancer -Current Market Size & Forecast Trends

The market for relapsed or refractory (R/R) colon cancer is expected to grow significantly, with the overall colorectal cancer therapeutics market projected to increase from approximately USD 22.36 billion in 2024 to around USD 75.39 billion by 2037, reflecting a compound annual growth rate (CAGR) of about 9.8% during this period. The growth is primarily driven by the rising prevalence of colorectal cancer globally, advancements in treatment options including chemotherapy, targeted therapies, and immunotherapies, as well as increasing awareness and screening efforts. In particular, the R/R segment benefits from ongoing research into novel therapies that improve patient outcomes and extend survival rates. As the market continues to evolve with new therapeutic developments and a growing patient population, significant expansion is anticipated through 2035.

Recurrent colon cancer may be treated with a combination of surgery and systemic therapies, such as chemotherapy, similar to the course of treatment for colon cancer that was initially diagnosed. Multiple lines of chemotherapy are typically used to treat patients with metastatic colorectal cancer that has relapsed or is refractory. Monoclonal antibodies that target the epidermal growth factor receptor (EGFR), such as anitumumab (Vectibix, Amgen) and cetuximab (Erbitux, Lilly), can be used to treat patients who do not have a RAS mutation. Patients with RAS mutations do not benefit from these medications, which limits their treatment options. In patients with refractory disease who have or do not have a RAS mutation, two oral medications have been demonstrated to increase survival. The tyrosine kinase inhibitor regorafenib (Stivarga, Bayer HealthCare) targets multiple pathways in the body. Additionally, it blocks serine-threonine kinases, including BRAF. The US Food and Drug Administration (FDA) approved regorafenib in 2012 for patients with metastatic colorectal cancer who had previously received treatment with fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy, an antivascular endothelial growth factor (VEGF) therapy, and an anti-EGFR therapy (if the patient is KRAS wild-type). For a comparable patient population, the FDA approved the combination drug Lonsurf, manufactured by Taiho Oncology and formerly known as TAS-102, in 2015. This treatment is cytotoxic. Regorafenib and TAS-102 both give patients options for late-line therapy. A locally directed procedure is an uncommon choice for patients who have relapsed or are resistant to treatment. In order to control the disease, radioactive yttrium-90 may occasionally be injected into the liver of patients with liver dominant disease. There is no impact of yttrium-90 on extrahepatic disease. Cytotoxic chemotherapy aims to make cells undergo apoptosis while they are dividing by targeting DNA division. Regorafenib and other targeted therapies try to disable the switch that causes cells to divide. Regorafenib's mechanism of action is very diverse. A number of tyrosine kinases, including VEGF receptors 1 through 3, TIE2, platelet-derived growth factor receptor, fibroblast growth factor receptors, KIT, and RET, are affected that are important for colon cancer replication. Regorafenib can therefore target tumor cells that have numerous mutations. In patients with refractory disease, one problem is that a tumor exposed to chemotherapy and targeted agents may, in response to evolutionary pressure, evolve into multiple cell lines that may be resistant to a single treatment. Regorafenib may be able to suppress resistant clones that are insensitive to a single drug with a single target due to its broad mechanism of action.

Report Highlights

R/R Colon Cancer - Current Market Trends

R/R Colon Cancer - Current & Forecasted Cases across the G8 Countries

R/R Colon Cancer - Market Opportunities and Sales Potential for Agents

R/R Colon Cancer - Patient-based Market Forecast to 2035

R/R Colon Cancer - Untapped Business Opportunities

R/R Colon Cancer - Product Positioning Vis-a-vis Competitors' Products

R/R Colon Cancer - KOLs Insight